Molecular Profiling METASTATIC, REFRACTORY, HER2+, BREAST PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE OVARIAN

Size: px
Start display at page:

Download "Molecular Profiling METASTATIC, REFRACTORY, HER2+, BREAST PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE OVARIAN"

Transcription

1 FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMTN AT , EXT Phase 1 REFMAL 381 (Phase 1 open at BAM only) Phase I Nivolumab and abraxane provided METASTATIC, REFRACTORY, HER2+, BREAST BRE- 200 (Phase 1 open at BAM only) Cabazitaxel/Lapatinib provided PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE A Phase 1, Open- Label, Multicenter, Safety Study of Nivolumab (BMS ) in Combination with nab- Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab- Paclitaxel/Carboplatin in Stage IIIB/IV Non- Small Cell Lung Cancer or nab- Paclitaxel in Recurrent Metastatic Breast Cancer A Study with Lead- In Safety Cohort of Cabazitaxel plus Lapatinib as Therapy for HER2- Positive Metastatic Breast Cancer Patients with Intracranial Metastases GU- 99: LOI GU Phase I Everolimus, Enzalutamide provided Enzalutamide plus Everolimus in Men with Metastatic Castrate- Resistant Prostate Cancer and Previous Treatment with Docetaxel: A Phase I Study with a Maximum Tolerated Dose Expansion Cohort OVARIAN REFMAL- 226: X82- CLI- 101 (BAM only; ON HOLD) Phase I X- 82 provided A Phase I, First in Human Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X- 82 in Subjects with Advanced Solid Tumors Molecular Profiling PRO- 02: ML28897 A Trastuzumab, Pertuzumab, Erlotinib, Vemurafenib, Vismodegib provided MY PATHWAY: An Open- Label A Study Evaluating Trastuzumab/ Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents Page 1 of 15

2 PRO- 11: CBGJ398XUS04 (pending) BGJ398 provided PRO- 12: CLDK378AUS23 (pending) Ceritinib provided PRO- 13: CLEE011XUS03 (pending) LEE011 provided Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 6 BGJ398 for patients with tumors with FGFR genetic alterations Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1 Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 8 LEE011 for patients with CDK4/6, Cyclin D1/3 or p16 activated tumors Bladder Clinical Trials GU- 113: GO29293 ( Cohort 2 CLOSED) MPDL3280A provided A, Multicenter, Single- Arm Study of MPDL3280A in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer Brain Clinical Trials SECOND- LINE CNS- 22: STML (pending 1 st Qtr) Phase I/II SL- 701, Montanide emulsion, imiquimod topical cream 5%, GM- CSF provided A Phase ½ Study of SL- 701, a Subcutaneously Injected Multivalent Gilioma- Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme Page 2 of 15

3 Breast Clinical Trials ADJUVANT, HER2+ BRE- 186 (Cohort A & B closed) Eribulin provided BRE- 233: BO28407 I TDM- 1 provided NEOADJUVANT, TNBC BRE- 238: M I Veliparib/Carboplatin provided FIRST- LINE, HR+, HER2- BRE- 234: CLEE011A2301 I LEE011 provided METASTATIC, FIRST- LINE, HER2- BRE- 252: LEE011E2301 (pending 2 nd qtr) I LEE011/placebo provided Phase 2 Trial of Eribulin in Patients Who do Not Achieve Pathologic Complete Response (pcr) Following Neoadjuvant Chemotherapy A Randomized, Multicenter, Open- Label Trial Comparing Chemotherapy plus Trastuzumab plus Pertuzumab versus Chemotherapy plus Trastuzumab Emtansine plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2- Positive Primary Breast Cancer A Randomized, Placebo- Controlled, Double- Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC) A Randomized, Double- Blind, Placebo- Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone Receptor Positive, HER2- Negative, Advanced Breast Cancer who Received no Prior Therapy for Advanced Disease A I randomized, double- blind, placebo- controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non- steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2- negative, advanced breast cancer Page 3 of 15

4 METASTATIC, FIRST- LINE, TNBC BRE- 223: ABI MBC- 001 /III Nab- Paclitaxel provided BRE- 231: CDX CDX- 011 provided BRE- 242: INCB Ruxolitinib/placebo provided Phase 2/3, Multi- center, Open- Label, Randomized Study of Weekly Nab- Paclitaxel (ABRAXANE) in Combination with Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First- Line Treatment in Subjects with ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer A Randomized Multicenter Study of CDX- 011 (CR011- vcmmae) in Patients with Metastatic, GPNMB Over- Expressing, Triple- Negative Breast Cancer A Randomized, Double- Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects With Advanced or Metastatic HER2- Negative Breast Cancer METASTATIC, SECOND- LINE, HER2+ BRE- 249: MM (pending 1 st qtr) MM- 302 provided METASTATIC, REFRACTORY, ER/PR POSITIVE BRE- 229: MDV Enzalutamide/placebo & Exemestane provided A Randomized, Multicenter, Open Label Study of MM- 302 plus Trastuzumab vs. Chemotherapy of Physician s Choice plus Trastuzumab in Anthracycline Naïve Patients with Locally Advanced/Metastatic HER2- Positive Breast Cancer A Phase 2, Randomized, Double- Blind, Placebo- Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination with Exemestane in Patients with Advanced Breast Cancer That is Estrogen or Progesterone Receptor- Positive and HER2- Normal BRE- 242: INCB Ruxolitinib/placebo provided A Randomized, Double- Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects With Advanced or Metastatic HER2- Negative Breast Cancer Page 4 of 15

5 METASTATIC, REFRACTORY, HER2+ BRE- 200 (Phase 1 open at BAM only) Cabazitaxel/Lapatinib provided BRE- 240: CL Enzalutamide provided METASTATIC, REFRACTORY, TNBC BRE- 231: CDX CDX- 011 provided BRE- 242: INCB Ruxolitinib/placebo provided SECOND- LINE, HER2-, HR+ BRE- 241: I3Y- MC- JPBN LY provided A Study with Lead- In Safety Cohort of Cabazitaxel plus Lapatinib as Therapy for HER2- Positive Metastatic Breast Cancer Patients with Intracranial Metastases Phase 2, Multicenter, Open- Label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer A Randomized Multicenter Study of CDX- 011 (CR011- vcmmae) in Patients with Metastatic, GPNMB Over- Expressing, Triple Negative Breast Cancer A Randomized, Double- Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects With Advanced or Metastatic HER2- Negative Breast Cancer A Phase 2 Study of LY for Patients with Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Colorectal/Rectal Clinical Trials METASTATIC, FIRST- LINE GI- 200: BP29262 RO , Bevacizumab provided A, Multicenter, Randomized, Double- Blind Study to Evaluate the Efficacy and Safety of RO Plus FOLFOX Versus Bevacizumab Plus FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer Page 5 of 15

6 METASTATIC, REFRACTORY GI- 190: PT023 (ON HOLD) I MABp1 provided METASTATIC, SECOND- LINE GI- 198: INCB I Ruxolitinib/placebo provided A Pivotal I Study to Evaluate Overall Survival using MABp1 as a Monotherapy in Metastatic Colorectal Cancer Patients with Cachexia A Randomized, Double- Blind Study of Ruxolitinib or Placebo in Combination with Regorafenib in Subjects with Relapsed or Refractory Metastatic Colorectal Cancer Esophageal/Gastric Clinical Trials NEOADJUVANT GI- 166 Lapatinib provided A Study with Lead- in Safety Cohort of 5- Fluorouracil, Oxaliplatin and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2 Positive Esophagogastric Adenocarcinoma METASTATIC, FIRST- LINE GI- 185: BO25114 I Pertuzumab/placebo, Trastuzumab provided GI- 208: I4T- MC- JVCU (pending 2 nd qtr) I Ramucirumab/placebo provided A Double- Blind, Placebo- Controlled, Randomized, Multicenter I Study Evaluating the Efficacy and Safety of Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patients with HER2- Positive Metastatic Gastroesophageal Junction and Gastric Cancer A Randomized, Double- Blind, Placebo- Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First- line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL) Page 6 of 15

7 METASTATIC, SECOND- LINE GI- 202: C26002 MLN0264 provided A Phase 2 Trial of MLN0264 in Previously Treated Patients with Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl cyclase (GCC) Kidney Clinical Trials METASTATIC, FIRST- LINE GU- 108: WO29074 MPDL3280A provided A, Randomized Study of MPDL2380A Administered as Monotherapy or in Combination with Bevacizumab versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma Lung Non Small Cell Clinical Trials STAGE IIIB/IV, FIRST- LINE LUN- 229 OGX- 427 provided Double- Blind Randomized Trial of Carboplatin and Pemetrexed with or without OGX- 427 in Patients with Previously Untreated Stage IV Non- Squamous Non- Small Cell Lung Cancer (Spruce Clinical Trials) LUN- 261: D6011C00002 (ON HOLD) AZD1775 provided LUN- 263: ABI NSCL- 003 I Nab- Paclitaxel provided Double- Blind Randomized Trial of Carboplatin and Pemetrexed with or without AZD1775 in Patients with Previously Untreated Stage IV Non- Squamous Non- Small- Cell Lung Cancer A I, Randomized, Open- Label, Crossover, Multi- Center, Safety and Efficacy Study to Evaluate Nab- Paclitaxel (ABRAXANE) as Maintenance Treatment After Induction with Nab- Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non- Small Cell Lung Cancer (NSCLC) Page 7 of 15

8 STAGE IIIB/IV, SECOND- LINE LUN- 291: EMR (pending 2 nd Qtr) I MSB C provided STAGE IIIB/IV, THIRD- LINE LUN- 283: D4191C0004 (pending 1 st Qtr) I MEDI4736 provided A I open- label, multicenter trial of MSB C versus docetaxel in subjects with PD- L1 positive non- small cell lung cancer that has progressed after a platinum- containing doublet A I, Open label, Randomised, Multi- centre, International Study of MEDI4736 versus Standard of Care in Patients with Locally Advanced or Metastatic Non- Small Cell Lung Cancer (Stage IIIB- IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum- based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) LOCALLY ADVANCED, UNRESECTABLE LUN- 282: D419C10001 I MEDI4736 RELAPSED/REFRACTORY LUN- 214 BKM120 provided LUN- 238: AT AT13387 LUN- 262: D6011C00001 (ON HOLD) AZD1175 provided A I, Randomised, Double- blind, Placebo- controlled, Multi- centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non- Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum- Based, Concurrent Chemoradiation Therapy (PACIFIC) Trial of Erlotinib and BMK120 in Patients with Advanced Non- Small- Cell Lung Cancer Previously Sensitive to Erlotinib A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non- Small Cell Lung Cancer (NSCLC) A Lead- in Multicentre, Randomized, Double- Blind Study Comparing AZD1175 plus Docetaxel and Placebo plus Docetaxel in Previously Treated Patients with p53 Non- Small- Cell Lung Cancer Page 8 of 15

9 LUN- 264: PPHM 1202 I Bavituximab provided LUN- 270: D4191C00003 MEDI4736 provided LUN- 284: I3Y- MC- JPBK I LY provided Lung Small Cell Clinical Trials EXTENSIVE STAGE, FIRST- LINE LUN- 244: 59R5-003 (pending 1 st qtr) Phase 1b/2 OMP- 59R5/placebo provided SUNRISE: A I, Randomized, Double- Blind, Placebo- Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone as Second- Line Therapy in Patients with Stage IIIB/IV Non- Squamous Non Small- Cell Lung Cancer A, Non- comparative, Open label, Multi- centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non- Small Cell Lung Cancer who have Received at Least Two Prior Systemic Treatment Regimens including One Platinum- based Chemotherapy Regimen (ATLANTIC) A Randomized Phase 3 Study of LY versus Erlotinib in Patients with Stage IV NSCLC with a detectable KRAS mutation who have progressed after platinum- based chemotherapy A Phase 1b/2 Study of OMP- 59R5 in Combination with Etoposide and Cisplatin in Subjects with Untreated Extensive Stage Small Cell Lung Cancer also now known as PINNACLE RTOG 0937 Randomized Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra- Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED- SCLC) RELAPSED/REFRACTORY, SECOND- LINE LUN- 286: ALDOXORUBICIN- P2- SCLC- 01 (pending 2 ndt Qtr) Phase 2b Aldoxorubicin and topotecan required A Multicenter, Randomized, Open- Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects with Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy Page 9 of 15

10 Ovarian Clinical Trials PHASE 1 REFMAL- 226: X82- CLI- 101 (BAM only; ON HOLD) Phase I X- 82 provided THIRD- LINE GYN- 41: ET743- OVC I Yondelis provided A Phase I, First in Human Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X- 82 in Subjects with Advanced Solid Tumors A Randomized, Open- Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced- Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Pancreas Clinical Trials ADJUVANT GI- 194: ABI PANC- 003 I Nab- Paclitaxel provided FIRST- LINE GI- 183: 59R5-002 OMP- 59R5 provided A Phase 3, Multicenter, Open- Label, Randomized Study of nab- Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma A Phase 1b/2 Study of OMP- 59R5 in Combination with Nab- Paclitaxel and Gemcitabine in Subjects with Previously Untreated Stage IV Pancreatic Cancer ALPINE: Antibody therapy in first- Line Pancreatic cancer Investigating anti- Notch Efficacy and safety Page 10 of 15

11 SECOND- LINE GI- 199: INCB I Ruxolitinib/placebo provided GI- 203: C26003 MLN0264 provided A Randomized, Double- Blinded Trial of Gemcitabine Plus Nab- Paclitaxel Combined with OGX- 427 or Placebo in Patients With Metastatic Pancreatic Cancer (The Rainier Trial) A Phase 2 Trial of MLN0264 in Previously Treated Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC) Prostate Clinical Trials PHASE 1, METASTATIC, RELAPSED/REFRACTORY GU- 99: LOI GU Phase I Everolimus, Enzalutamide provided Enzalutamide plus Everolimus in Men with Metastatic Castrate- Resistant Prostate Cancer and Previous Treatment with Docetaxel: A Phase I Study with a Maximum Tolerated Dose Expansion Cohort Radiation Clinical Trials ED - SCLC RTOG 0937 Randomized Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra- Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED- SCLC) Page 11 of 15

12 Hematological Malignancies LYM- 89: GS- US GS A Phase 2 Open Label, Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS in Patients with Relapsed or Refractory Hematologic Malignancies CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FIRST- LINE CLL- 32: GS- US (ON HOLD) I IDELA/placebo provided A Phase 3, Randomized, Double- Blind, Placebo- Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia CLL- 34: PCYC CA (pending 2 nd Qtr) I Ibrutinib, chlorambucil, and obinutuzumab provided A Randomized, Multicenter, Open- label, Phase 3 Study of the Bruton s Tyrosine Kinase Inhibitor Ibrutinib in Combination with Obinutuzumab versus Chlorambucil in Combination with Obinutuzumab in Subject s with Treatment- Naïve Chronic Lymphocythic Leukemia or Small Lymphocytic Lymphoma Relapsed/Refractory CLL- 18: LOI CLL Ofatumumab CLL- 30: IPI I IPI- 145, Ofatumumab provided CLL- 31: IPI Rollover IPI- 145, Ofatumumab provided Trial: Rapid infusion of Ofatumumab in Patients with Previously Treated CLL A Phase 3 Study of IPI- 145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma A Study of IPI- 145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI (CLL- 30 Rollover Study) Page 12 of 15

13 SECOND- LINE CLL- 35: UTX- IB- 301 (pending 2 nd Qtr) I Ublituximab provided A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib Alone, in Patients with Previously Treated High- Risk Chronic Lymphocytic Leukemia (CLL) CHRONIC MYELOGENOUS LEUKEMIA (CML) SECOND- LINE CML- 18: CA Phase IV Dasatinib provided An Open Label, Randomized Phase IV Study of Dasatinib vs. Imatinib in the Treatment of Subjects with Chronic Phase Chronic Myeloid Leukemia who Have not Optimally Responded to 3 Months of Therapy with 400 mg Imatinib HODGKINS DISEASE FIRST- LINE LYM- 84: C25003 I Brentuximab vedotin provided A Randomized, Open- label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma NON- HODGKIN S LYMPHOMA- FOLLICULAR FIRST- LINE LYM- 99: GS- US (pending 2 nd Qtr) Idelalisib provided A Phase 2, Single Arm Study Evaluating the Safety and Efficacy of Idelalisib in Combination with Rituximab for Previously Untreated Indolent Non- Hodgkin Lymphoma RELAPSED/REFRACTORY LYM- 87: IPI IPI- 145 provided A Phase 2 Study of IPI- 145 in Subjects with Refractory Indolent NHL Page 13 of 15

14 MULTIPLE MYELOMA MM- 56: CFZ013 (pending 1 st Qtr) Phase Ib Carfilzomib provided FIRST LINE E1A11 I Carfilzomib provided MM- 58: MMY3008 (pending 2 nd Qtr) I Daratumumab provided RELAPSED/REFRACTORY MM- 42: LOI BMT Phase I/II MLN9708 provided MM- 47 (pending 4 th Qtr) Phase Ib/III Oprozomib provided Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma E1A11, Randomized I Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintanANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) Principal A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy A Phase I/II study evaluating maintenance MLN9708 following an allogeneic transplant for multiple myeloma Phase 1b/3 Multicenter STudy of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects MYELODYSPLASTIC SYNDROME MDS- 16: TL RAN PTL Birinapant provided A Phase 2, Randomized, Double- Blind, Placebo- Controlled Study of Azacitidine with or without Birinapant with a Single Arm Open- Label Run- In Phase in Subjects with Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Page 14 of 15

15 MYELOPROLIFERATIVE NEOPLASMS MPN- 06: PAC326 I Pacritinib provided A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post- Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Page 15 of 15

Phase 1 HEMATOLOGY METASTATIC, REFRACTORY, HER2+, BREAST. REFMAL 381 (Phase 1 open at BAM only) Phase I Therapeutic Nivolumab and abraxane provided

Phase 1 HEMATOLOGY METASTATIC, REFRACTORY, HER2+, BREAST. REFMAL 381 (Phase 1 open at BAM only) Phase I Therapeutic Nivolumab and abraxane provided FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMENT AT 1-800- 710-4674 Phase 1 REFMAL 381 (Phase 1 open at BAM only) Phase

More information

Phase 1 HEMATOLOGY. GI- 219: BBI (pending 1 st Qtr) Phase Ib Therapeutic BBI608 provided

Phase 1 HEMATOLOGY. GI- 219: BBI (pending 1 st Qtr) Phase Ib Therapeutic BBI608 provided FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS, PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTMENT AT 1-800- 710-4674 Phase 1 GI- 219: BBI608-246 (pending 1 st Qtr) Phase

More information

Phase 1 SOLID TUMOR HEMATOLOGY

Phase 1 SOLID TUMOR HEMATOLOGY FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTMENT AT 513-710- 4674, EXT 27110 Phase 1 SOLID TUMOR BRE- 261: GO29831 (BAM

More information

CLINICAL TRIALS ACC. Jul 2016

CLINICAL TRIALS ACC. Jul 2016 CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list. February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of

More information

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on

More information

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab

More information

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles 2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla

More information

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are

More information

Cancer drug approvals for paediatric indications (n=43)

Cancer drug approvals for paediatric indications (n=43) Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December

More information

Title Cancer Drug Phase Status

Title Cancer Drug Phase Status Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/

More information

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please

More information

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2

More information

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal

More information

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

All Studies by Indication

All Studies by Indication Therapeutic Area Protocol Number Drug/Device Phase Description Advanced malignancies 337 20101132 AMG 337 I " A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of

More information

Summary of Research and Writing Activities in Oncology

Summary of Research and Writing Activities in Oncology Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,

More information

MEDICAL PRIOR AUTHORIZATION

MEDICAL PRIOR AUTHORIZATION MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

I. Diagnosis of the cancer type in CUP

I. Diagnosis of the cancer type in CUP Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:

More information

JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2014

JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2014 JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2014 15 years of excellence in patient care, research, and education The Promise of Medicine: The research team at Johns Hopkins Singapore provides unparalleled

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from

More information

OPEN TRIALS Accruals counted until 30-April Current Accrual

OPEN TRIALS Accruals counted until 30-April Current Accrual Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine

More information

Studienverzeichnis Medizinische Onkologie

Studienverzeichnis Medizinische Onkologie Studienverzeichnis Medizinische Onkologie Mammakarzinom, Gynäkologie 21/12 24/14 25/14 96/12 PALLAS I I Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-her2 negative and triple negative-androgen

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982

More information

Open Trials as of end of March 2016

Open Trials as of end of March 2016 EORTC 10085 PRO EORTC 10085 prospective part, Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG inter study 30 30-Jun-2016 estelle.cassoly@sakk.ch IBCSG

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Roche Investor Relations ASCO Planner 2016

Roche Investor Relations ASCO Planner 2016 Roche Investor Relations ASCO Planner 2016 Friday, June 3 Session Title: Pediatric Oncology I Date: Fri, June 3 Location: S504 Time: 3:00 PM - 6:00 PM Speaker Name: Veronique Minard-Colin 5:12 PM - 5:24

More information

Date of HRA. Date Site Invited. Date Site Selected. Approval. Recruited. Date

Date of HRA. Date Site Invited. Date Site Selected. Approval. Recruited. Date 14/LO/0259 134883 RE-AKT: A randomised Phase II study of enzalutamide (MDV3100) in combination with AZD5363 in s with Metastatic Castration - Resistant Prostate Cancer Yes 08/01/2018 01/07/2016 01/07/2017

More information

Keytruda (pembrolizumab)

Keytruda (pembrolizumab) Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The

More information

A JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2015

A JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2015 A JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2015 15 years of excellence in patient care, research, and education The Promise of Medicine: The research team at Johns Hopkins Singapore provides unparalleled

More information

CancerPACT Cancer Patients Alliance for Clinical Trials

CancerPACT Cancer Patients Alliance for Clinical Trials TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal

More information

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG

More information

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015 Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib

More information

CENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36)

CENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36) CENTER FOR CLINICAL TRIALS St. Luke s Medical Center Ongoing Clinical Trials CANCER INSTITUTE (36) BLOOD TITLE : A Randomized, Two By Two Arm, Multicenter, Open-Label Phase III Study Of BMS-354825 Administered

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study A221101 ALLIANCE NCT01781468 Brain A Phase III Randomized, Double-Blind Placebo Controlled Study of

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List A031501 ALLIANCE NCT03244384 Bladder Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) Versus Observation NHLBI-MDS

More information

Open NCT NCT Open NCT

Open NCT NCT Open NCT Updated Feb 18/16. Please note, although every effort is made to keep this list as up-to-date as possible, some trial status updates may not be reflected in the list below. DST Project Title Project Display

More information

Min number of patients agreed to be recruited. Max number of patients agreed to be recruited

Min number of patients agreed to be recruited. Max number of patients agreed to be recruited be 12/SC/0139 98125 A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI- CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS

More information

CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship

CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship CancerPACTS Cancer Patients Alliance for Clinical Trials and Survivorship Listing of Cancer Clinical Trials Silicon Valley area of California Summer / Fall 2011 Solid Tumors 1. Breast. 2 2. Central Nervous

More information

Studies proceeding under pre HRA-Approval system (NHS Permission)

Studies proceeding under pre HRA-Approval system (NHS Permission) 15/NW/0004 162679 Studies proceeding under pre HRA-roval system (NHS Permission) A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

BREAST. POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study

BREAST. POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study BREAST Advanced breast Cancer, metastatic breast cancer HER2 Negative Metastatic or Locally Advanced Unresectable BRCA Associated Breast Cancer Pfizer A5481082 NCT03280303 AbbVie M12-914 NCT02163694 POLARIS:

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

CDK4 and CDK6 Inhibitor

CDK4 and CDK6 Inhibitor CDK4 and CDK6 Inhibitor Abemaciclib, LY2835219 Derived from Shapiro GI. 1 Drug Discovery Platform: Cancer Cell Signaling JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 5: March 23, 2011 The Clinical Research E-News Now Open: CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

National Cancer Drugs Fund List Ver4.4

National Cancer Drugs Fund List Ver4.4 National Cancer Drugs Fund List Ver4.4 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Control Version Date Revision summary Ver1.0 19 Mar 2014 Update following

More information

Triple Negative Breast Cancer: Part 2 A Medical Update

Triple Negative Breast Cancer: Part 2 A Medical Update Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is

More information

Development status of ONO-4538(nivolumab)1

Development status of ONO-4538(nivolumab)1 Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 6: ISSUE 5: May 14, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Receiving Adjuvant Trastuzumab. A randomized double-blind, placebocontrolled

Receiving Adjuvant Trastuzumab. A randomized double-blind, placebocontrolled DST Study Protocol acronym Study Title Site Status Detail Determining the Cardiac Biomarker Profile in Breast Cancer Patients Cardiac Biomarker Receiving Adjuvant Trastuzumab Breast (Cabot) CABOT Therapy

More information

List of Actively Accruing Cancer Clinical Trials. DST Study Protocol acronym Project Title Site status detail Clinical trials gov number

List of Actively Accruing Cancer Clinical Trials. DST Study Protocol acronym Project Title Site status detail Clinical trials gov number Breast ALTENS(Hot Flash Study) Hot Flash Study A Phase II Study of Acupuncture-like trancutaneous electrical nerve stimulation in the management of vasomotor symptoms induced by breast cancer treatments.

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Development status of ONO-4538(nivolumab)1

Development status of ONO-4538(nivolumab)1 Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1

More information

Breast Cancer Clinical Trials in Georgia

Breast Cancer Clinical Trials in Georgia www.georgiacore.org www.georgiatrials.org Breast Clinical Trials in Georgia Breast in Georgia: The Facts As the leading cause of cancer incidence among Georgia females, breast cancer accounts for 32 percent

More information

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells

More information

National Cancer Drugs Fund List Ver4.0

National Cancer Drugs Fund List Ver4.0 National Cancer Drugs Fund List Ver4.0 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Contro VersDate Revision summary Ver 19 Mar 201 Update following Mar-14

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

An D. Nguyen, MD Curriculum Vitae

An D. Nguyen, MD Curriculum Vitae OFFICE/ BUSINESS ADDRESS: Pacific Shores Medical Group 19582 Beach Blvd, Suite 212 Huntington Beach, CA 92648 Phone: (714) 252-9415 Fax: (714) 963-8407 ADDITIONAL OFFICE: 16300 Sand Canyon Avenue, Suite

More information

IRB INDICATION Number ENROLLED

IRB INDICATION Number ENROLLED Revised 1/6/2011 OPEN TRIALS 2006-2011 INDICATION Number ENROLLED SPONSOR Title Provided Phase I AZA PH US 2007 PK 006 Celgene A Phase I, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics

More information

Cancer Therapy Update in 2017

Cancer Therapy Update in 2017 Cancer Therapy Update in 2017 Editor: Le Wang, M.D., Ph.D Medical Oncology and Hematology (Board-Certified) Ibrutinib (Imbruvica) Pharmacyclics 1 /19/2017 Lymphoma Marginal Zone Lymphoma (MZL), Relapsed/Refractory

More information

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Media Release Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal combination

More information

StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient

StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in

More information

HRA Approval Date Site Date Site Sponsor. Non- Confirmation Status. Date Site Ready To Start

HRA Approval Date Site Date Site Sponsor. Non- Confirmation Status. Date Site Ready To Start Research Ethics Committee Reference Number Integrated Research Application System Number Submission Type Name of Trial Date of Receipt of Date of Valid Research Application First Patient Recruited? Date

More information

National Cancer Drugs Fund List Ver2.1

National Cancer Drugs Fund List Ver2.1 National Cancer Drugs Fund List Ver2.1 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Control Version Date Revision summary Ver1.0 19 Mar 2014 Update following

More information

A JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2016

A JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2016 A JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2016 The Promise of Medicine: The research team at Johns Hopkins Singapore provides unparalleled excellence in their search for ground breaking treatment

More information

Etudes cliniques Service d Oncologie - Radiothérapie

Etudes cliniques Service d Oncologie - Radiothérapie Etudes cliniques Service d Oncologie - Radiothérapie Décembre 2017 SEIN NEO ADJUVANT WO39392 (Impassion 031) : A phase III randomized study to investigate the efficacy and safety of Atezolizumab in combination

More information

Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers

Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers Program 7:15 7:40 Translocations as predictive biomarkers in lung cancer: Overview Mari Mino Kenudson, MD 7:40 8:05 Translocation

More information

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Investor Update Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the

More information

For Health Professionals Who Care For Cancer Patients

For Health Professionals Who Care For Cancer Patients April 2018 Volume 21, No. 4 For Health Professionals Who Care For Cancer Patients Inside This Issue: Editor s Choice New Programs: Palbociclib for Metastatic Breast Cancer, Adjuvant Capecitabine for Breast

More information

ASCO 2014 Highlights*

ASCO 2014 Highlights* ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s

More information

Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer

Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at

More information

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 07.01.18 Last Review Date: 11.17 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the

More information

Media Release. Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Media Release. Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting Media Release Basel, 3 May 2016 Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 19 Roche medicines are included in

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 8: May 5, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: E2906, Phase III randomized

More information

Our Clinical Trials. Oncology

Our Clinical Trials. Oncology Our Clinical Trials Oncology ANGIOGENESIS Trebananib (AMG 86) (angiopoietin inhibitor) ANTIBODY DRUG CONJUGATE, continued AMG 595 (anti-egfrviii) Trebananib With Paclitaxel and Trastuzumab or Capecitabine

More information

Etudes cliniques Service d Oncologie - Radiothérapie

Etudes cliniques Service d Oncologie - Radiothérapie Etudes cliniques Service d Oncologie - Radiothérapie Juillet 2017 SEIN NEO ADJUVANT Neo-RHEA : NEOadjuvant Biomarker ResearcH Study of Palbociclib in Estrogen Receptor Positive HER2 Negative Breast CAncer

More information

MEDICAL NECESSITY GUIDELINE

MEDICAL NECESSITY GUIDELINE PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information